2170.Hk
The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the production and sale of pharmaceutical products.
Business. The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the production and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the production and sale of pharmaceutical products.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.37, indicating a relatively conservative approach to financing. The liquidity position is strong, as evidenced by a current ratio of 3.98, suggesting the company has sufficient short-term assets to cover its liabilities. The price-to-book ratio of 0.44 indicates that the company's market value is significantly lower than its book value, which may suggest undervaluation or underlying financial distress.
Profitability metrics reveal a challenging financial situation, with a negative return on equity of -23.91% and a negative return on assets of -15.45%, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at -214.08 million, and the net income is also negative at -223.46 million, highlighting significant operational losses.
The company's revenue is concentrated in a single segment, as no specific segments are disclosed, and there is no geographic breakdown provided in the available data. This lack of diversification may expose the company to higher risks if market conditions in its primary market deteriorate.
The company's growth trajectory is uncertain, as there are no specific growth metrics or outlooks provided in the available data. The recent financial performance, marked by significant losses, suggests a need for strategic adjustments to improve profitability and operational efficiency.
Risk factors include the company's negative net income and operating income, which may affect its ability to sustain operations and meet financial obligations. The dilution potential is low, as there are no immediate filing-based liquidity or dilution flags detected. The company has not made any adjustments to its valuations, indicating that the current financial metrics are based on standard accounting practices.
Recent events, such as filings and transcripts, are not detailed in the available data, making it difficult to assess any recent strategic or operational changes that may impact the company's future performance.
- The company has a strong liquidity position with a current ratio of 3.98.
- The company is experiencing significant operational losses, with a negative operating income of -214.08 million.
- The company's market value is significantly lower than its book value, as indicated by a price-to-book ratio of 0.44.
- The company's profitability metrics are negative, with a return on equity of -23.91% and a return on assets of -15.45%.
- The company's financial structure is relatively conservative, with a low debt-to-equity ratio of 0.37.
- **margin_outlook_rationale**: The company's margin outlook is negative due to significant operational losses and a negative return on equity.
- **rd_outlook_rationale**: No specific information is available to assess the company's research and development outlook.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 2170.HK Market data — financials · 2026-05-26